About www.inflamedinc.com
Our Story
- Millions in the United States and across the globe suffer from neurodegenerative and neuroinflammatory disorders
- Recent research suggests that upregulated complement system is one of the key mediators of neuroinflammation and subsequent neurodegeneration
- With more than 30 years of experience in research and development, we have developed a proprietary product for treating neuroinflammation in disorders of the brain.
- We have established the safety of our product in animal models such as rodents and baboons.
Our Team
At www.inflamedinc.com, we are committed to integrity, excellence, and innovation in everything we do. We have the knowledge, expertise, commitment and business acumen to develop an efficient therapy to treat complement mediated neuroinflammation. Girish J. Kotwal, Ph.D. is the Founder, President and CEO, Jianhua Zhou, Ph.D., MBA is the Vice president & Business Development (BD) Lead, and Amod kulkarni, Ph.D. is quality, scientific and regulatory science / affairs specialist of the company.
Our Vision
Our vision is to fulfil the unmet healthcare needs of millions around the globe and provide affordable healthcare solution to the individuals suffering from neuroinflammatory and neurodegenerative disorders of the brain and further extend our approach to other indications. We would like to reach the people of all colors, races and gender through our affordable innovative solution for treating brain disorders.
Our Approach
At www.inflamedinc.com, we are committed to integrity, excellence, and innovation in everything we do. We would like to follow a collaborative approach for investigational new drug (IND) studies and market authorization approval (MAA) of our novel proprietary protein therapeutics developed with a strong scientific background and sound POC studies. Currently, we have been supported through the small business research innovation (SBIR) phase-I grant. In addition to the government funding, we are actively looking for fruitful partnerships and / or financing from the angel and other private investors.
Our Patents and Publications
InflaMed Inc’s intellectual property status is based on the discoveries made by Dr. Girish Kotwal's laboratory. the first patent was issued while at the Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of health, USA. Our product is protected by the US patents for various indications. In addition, we expect at least one patent based on the recently generated data. Our current focus is on disorders of the brain, although we have patents for other indications.
We have published our research in the journal of high impact factors such as Nature, Science, Biogerontology etc.